Recent progress in the use of genetics to understand links between type 2 diabetes and related metabolic traits
© BioMed Central Ltd 2013
Published: 28 March 2013
Skip to main content
© BioMed Central Ltd 2013
Published: 28 March 2013
Genome-wide association studies have identified genetic variants associated with increased risk of type 2 diabetes. The aim of this review is to highlight some of the insights into the mechanism underlying type 2 diabetes provided by genetic association studies.
Evidence for links between diabetes and related metabolic traits from genetic studies
Fasting glucose in the normal range
Type 2 diabetes
GCK and MTN1RBG6PC2
Variants at these loci have the strongest effects on fasting glucose but relatively small effects on risk of type 2 diabetesFasting glucose increasing allele is paradoxically associated with improved response to an oral glucose challenge
Variants in the melatonin receptor MTNR1B are associated with increased fasting glucose, impairment of insulin secretion from the pancreatic beta cell, and increased risk of type 2 diabetes
Inflammatory marker CRP
Obesity and metabolic syndrome phenotypes
CRP has no causal effect on obesity and development of insulin resistance and type 2 diabetes, suggesting inflammation is not causally linked to obesity
Obesity causally affects the circulating levels of CRP
Type 2 diabetes
Raised circulating SHBG levels reduce the risk of type 2 diabetes
Type 2 diabetes
CDKAL1, HHEX/IDE and ADCY5
Genetic variants that influence birth weight also influence type 2 diabetes risk
Genetic studies have revealed that polymorphisms in the MTNR1B gene influence the risk of type 2 diabetes and glucose control in the non-diabetic population. MTNR1B encodes one of two distinct receptors through which melatonin exerts its effect . Melatonin is a circulating hormone that regulates circadian rhythm. The MTNR1B receptor is expressed in human islets [22, 23]. Increased nocturnal levels of melatonin coincide with decreased insulin levels. There is evidence from animal studies that if the central and peripheral circadian rhythms, including the melatonin pathway, are disrupted, the risk of metabolic disorders and type 2 diabetes is increased [24, 25]. The association between MTNR1B genetic variation and glucose control appears to be driven by a primary effect on insulin secretion . The variants in MTNR1B are also associated with alterations to MTNR1B gene expression in human islet samples - the type 2 diabetes risk and glucose raising allele is associated with increased MTNR1B expression . A large-scale exon sequencing study of the MTNR1B locus in more than 7,000 Europeans revealed 36 very rare variants (minor allele frequency <0.1%) associated with type 2 diabetes risk . Four of these rare variants caused complete loss of melatonin binding and signaling capabilities . It is not clear why rare reduced function mutations are associated with increased type 2 diabetes risk and a common allele that increases MTNR1B gene expression is also associated with increased risk. One suggestion is that the increased expression could be the result of the absence of negative feedback regulatory events under conditions of impaired melatonin receptor signaling .
Genetic studies have provided important insights into the relationships between obesity, inflammation and diabetes. Obesity is associated with a multitude of adverse metabolic traits, including insulin resistance, non-alcoholic fatty liver disease, hyperglycemia, hypertension and dyslipidemia. One intriguing association is that between inflammation and obesity, but the causal direction is unknown. GWASs have identified genetic variants associated with obesity, and variants associated with inflammation. Variants in the FTO gene are associated with obesity and variants in the C-reactive protein (CRP) gene are associated with C-reactive protein (CRP) levels - an inflammatory marker synthesized by the liver. FTO associates with multiple metabolic phenotypes to the extent expected based on its association with BMI and the correlations between BMI and secondary metabolic phenotypes . These associations include FTO versus circulating CRP levels . In contrast CRP genetic variants are not associated with obesity . These findings suggest that inflammatory markers, particularly CRP, do not causally influence the risk of obesity. This finding provides evidence that the subclinical inflammatory profile associated with obesity is more likely to be secondary to adiposity rather than causal. The causal effect of obesity on inflammatory markers is likely to be driven by adipocytes that are a key expresser of inflammatory molecules [29–31].
Recent genetic studies have highlighted a possible causal role for lower sex hormone binding globulin (SHBG) levels and increased risk of type 2 diabetes. This evidence comes from studies of genetic variation in the SHBG gene.
SHBG, a plasma transport protein that is mainly produced by the liver, binds to sex hormones: estradiol, and with higher affinity to testosterone. It was assumed that SHBG plays one role only, which is regulation of free sex hormone bioavailability to target tissues. However, several physiologic roles have been suggested for SHBG through its multiple interactions with its receptor; these roles include modification of sex hormone uptake and cell proliferation [32–34]. The multiple interactions between SHBG and its receptors in various target tissues suggest that the role is more complex than the simple transport of sex hormones in serum.
Evidence of links between SHBG and sex hormones and insulin resistance/type 2 diabetes from non-genetic studies
Effect on insulin secretion/resistance
Evidence that SHBG is upstream of type 2 diabetes
Altered levels of sex hormones
Increased risk of type 2 diabetes
PCOS in women
Elevation in levels of androgens
Increased risk of non-insulin-dependent diabetes mellitus
Randomized controlled trial
Androgen supplementation in men with low testosterone levels
Increased insulin sensitivity
Animal model (male mouse)
Lack of androgen receptor
Animal model (female rat)
Treatment with testosterone after oophorectomy
Evidence that SHBG is downstream of type 2 diabetes
In vitro study
Incubation of hepatoblastoma cell line with IGF-I
Decreased SHBG levels
Animal model (mouse) and in vitro study
Increased fasting glucose
Downregulation of SHBG expression
Insulin lowering interventions in non-diabetic men and women (without PCOS)
Increased SHBG levels
Study of obese women with PCOS
Increase insulin levels
Reduced serum SHBG levels
Two Mendelian randomization analyses, using genetic variants at the SHBG locus, have provided evidence that raised circulating SHBG levels reduce the risk of type 2 diabetes [35, 36]. In both studies, the effects of SHBG variants on risk of type 2 diabetes were consistent with those predicted by the effect of the SNPs on SHBG levels and the correlation between SHBG levels and type 2 diabetes.
Numerous epidemiological studies have shown that reduced birth weight is associated with impaired glucose tolerance and type 2 diabetes. There are two hypotheses proposed to explain the association between birth weight and type 2 diabetes. (a) The fetal programming hypothesis proposes that poor intra-uterine nutrition will not only cause small, thin babies, but also programs the development of risk factors of disease, such as type 2 diabetes in adults [37, 38]. (b) The fetal insulin hypothesis suggests that fetal genetics influencing insulin secretion and action have a direct effect on small, thin babies and their increased risk of type 2 diabetes . Maternal genes such as GCK and TCF7L2 can indirectly, through their effect on intra-uterine glucose levels, influence fetal growth [40, 41]. The hypothesis suggests that the glucose raising variants in mothers increase the birth weight of offspring because the fetal pancreas is exposed to more glucose and therefore secretes more insulin. In contrast, the genetic variants at CDKAL1, HHEX/IDE and ADCY5 loci are associated with birth weight through fetal genotype independently of maternal genotype [40–43]. Variants at the CDKAL1, HHEX/IDE and ADCY5 loci are all associated with insulin secretion and their association with birth weight suggests the mechanism starts in prenatal life. The association of three type 2 diabetes loci, CDKAL1, HHEX/IDE and ADCY5, with birth weight is consistent with the fetal insulin hypothesis. The assessment of the role of the remaining 62 type 2 diabetes loci with birth weight could elucidate whether type 2 diabetes loci in addition to CDKAL1, HHEX/IDE and ADCY5 also influence prenatal growth.
The genetic links between type 2 diabetes and metabolic traits have highlighted possible new biological pathways. Nevertheless, genetic association studies have some limitations. One caveat is that the variant discovered by GWASs may not be the actual causal variant but just linked to it on a chromosome (linkage disequilibrium). Indeed, the causal variant could be in a nearby gene or non-genic region. The other limitation is that the variants discovered to be associated with complex traits explain a very small proportion of individual variation in disease risk or trait levels. These small effect sizes have compromised the disease predictive value of common genetic variants. One explanation is that common diseases such as type 2 diabetes are caused not only by many common variants with small effect but also by rare variants with larger effect that would not be detected in a GWAS. With the advent of high-throughput platforms and methods, full sequencing of samples could make it feasible to assess structural variants and rare variants and discover more of the heritable component to type 2 diabetes.
In summary, we have presented a number of examples of how genetics helps us understand the complex associations between type 2 diabetes and many other metabolic traits, including glucose homeostasis, circadian rhythm, SHBG, inflammation and birth weight.
GWASs, which do not rely on a prior understanding of disease biology, have resulted in remarkable progress in our understanding of the genetic underpinnings of type 2 diabetes in the last 5 years. We anticipate that advances in technology and resources, including very large sample sizes such as the 500,000 individuals available in the UK Biobank, will lead to even more progress in understanding the highly complex genetic and non-genetic risk factors for metabolic diseases.
body mass index
genome-wide association study
sex hormone binding globulin
single nucleotide polymorphism.